Johnson & Johnson (NYSE:JNJ) received FDA approval for its TECNIS PureSee IOL, an extended depth of focus intraocular lens ...

The TECNIS PureSee IOL addresses both cataract-related vision loss and presbyopia, which affects near vision as eyes age.

FDA approval supports US commercialization of TECNIS PureSee, an EDOF IOL for implantation during cataract surgery, with availability anticipated later in 2026. PureSee is positioned to preserve ...

The Tecnis PureSee IOL is the first FDA-approved extended depth of focus IOL maintaining contrast sensitivity comparable to ...

Johnson & Johnson (JNJ) wins FDA approval for Tecnis PureSee intraocular lens ((IOL)), giving eye surgeons a new lens option for use in cataract surgery. Read more here.

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients ...

Johnson & Johnson (NYSE: JNJ) announced that it received FDA approval for its Tecnis PureSee intraocular lens (IOL) for cataract surgery.

PanOptix delivers an exceptional combination of near, intermediate and distance vision and substantially reduces the need for glasses 1,2 More than ninety-nine percent of PanOptix patients in the FDA ...

TORONTO, Feb. 1, 2021 /CNW/ - Alcon, the global leader in eye care, is pleased to announce a nationwide launch of the Clareon ® intraocular lens (IOL) with the AutonoMe ® delivery system in Canada.

The FDA approved the Tecnis PureSee IOL, an extended depth of focus IOL for cataract surgery, according to a press release ...

PanOptix is already one of the leading presbyopia-correcting IOLs in more than 70 countries. It is designed for today’s active lifestyles, from viewing mobile devices and computer screens to ...